Taiwan · Delayed Price · Currency is TWD BIONET Statistics
Total Valuation
BIONET has a market cap or net worth of TWD 4.00 billion. The enterprise value is 3.70 billion.
| Market Cap | 4.00B |
| Enterprise Value | 3.70B |
Important Dates
The next estimated earnings date is Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | Oct 1, 2026 |
Share Statistics
BIONET has 50.31 million shares outstanding. The number of shares has decreased by -0.83% in one year.
| Current Share Class | 50.31M |
| Shares Outstanding | 50.31M |
| Shares Change (YoY) | -0.83% |
| Shares Change (QoQ) | -0.41% |
| Owned by Insiders (%) | 5.44% |
| Owned by Institutions (%) | 1.68% |
| Float | 40.95M |
Valuation Ratios
The trailing PE ratio is 77.94.
| PE Ratio | 77.94 |
| Forward PE | n/a |
| PS Ratio | 3.23 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 3.22 |
| P/FCF Ratio | 163.78 |
| P/OCF Ratio | 27.02 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 77.25, with an EV/FCF ratio of 151.42.
| EV / Earnings | 71.90 |
| EV / Sales | 2.99 |
| EV / EBITDA | 77.25 |
| EV / EBIT | n/a |
| EV / FCF | 151.42 |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.62 |
| Quick Ratio | 4.22 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 2.38 |
| Debt / FCF | 4.66 |
| Interest Coverage | -9.64 |
Financial Efficiency
Return on equity (ROE) is 0.04% and return on invested capital (ROIC) is -0.07%.
| Return on Equity (ROE) | 0.04% |
| Return on Assets (ROA) | -0.29% |
| Return on Invested Capital (ROIC) | -0.07% |
| Return on Capital Employed (ROCE) | -0.54% |
| Weighted Average Cost of Capital (WACC) | 6.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 5.34 |
Taxes
In the past 12 months, BIONET has paid 18.43 million in taxes.
| Income Tax | 18.43M |
| Effective Tax Rate | 95.60% |
Stock Price Statistics
The stock price has decreased by -11.17% in the last 52 weeks. The beta is 0.47, so BIONET's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -11.17% |
| 50-Day Moving Average | 96.49 |
| 200-Day Moving Average | 86.77 |
| Relative Strength Index (RSI) | 28.83 |
| Average Volume (20 Days) | 365,698 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BIONET had revenue of TWD 1.24 billion and earned 51.43 million in profits. Earnings per share was 1.02.
| Revenue | 1.24B |
| Gross Profit | 683.87M |
| Operating Income | -14.47M |
| Pretax Income | 19.28M |
| Net Income | 51.43M |
| EBITDA | 47.87M |
| EBIT | -14.47M |
| Earnings Per Share (EPS) | 1.02 |
Balance Sheet
The company has 1.40 billion in cash and 113.80 million in debt, with a net cash position of 1.29 billion or 25.58 per share.
| Cash & Cash Equivalents | 1.40B |
| Total Debt | 113.80M |
| Net Cash | 1.29B |
| Net Cash Per Share | 25.58 |
| Equity (Book Value) | 2.26B |
| Book Value Per Share | 25.37 |
| Working Capital | 1.47B |
Cash Flow
In the last 12 months, operating cash flow was 148.04 million and capital expenditures -123.62 million, giving a free cash flow of 24.42 million.
| Operating Cash Flow | 148.04M |
| Capital Expenditures | -123.62M |
| Depreciation & Amortization | 62.33M |
| Net Borrowing | -8.11M |
| Free Cash Flow | 24.42M |
| FCF Per Share | 0.49 |
Margins
Gross margin is 55.30%, with operating and profit margins of -1.17% and 4.16%.
| Gross Margin | 55.30% |
| Operating Margin | -1.17% |
| Pretax Margin | 1.56% |
| Profit Margin | 4.16% |
| EBITDA Margin | 3.87% |
| EBIT Margin | -1.17% |
| FCF Margin | 1.97% |
Dividends & Yields
This stock pays an annual dividend of 1.42, which amounts to a dividend yield of 1.78%.
| Dividend Per Share | 1.42 |
| Dividend Yield | 1.78% |
| Dividend Growth (YoY) | -38.40% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 136.24% |
| Buyback Yield | 0.83% |
| Shareholder Yield | 2.61% |
| Earnings Yield | 1.29% |
| FCF Yield | 0.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 19, 2024. It was a forward split with a ratio of 1.070923771.
| Last Split Date | Sep 19, 2024 |
| Split Type | Forward |
| Split Ratio | 1.070923771 |
Scores
BIONET has an Altman Z-Score of 4.04 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.04 |
| Piotroski F-Score | 3 |